REGENTIS BIOMATERIALS LTD. (RGNT) Form 6-K — Jun 18, 2026
Regentis Biomaterials Ltd. entered into definitive securities purchase agreements to sell an aggregate of 1,844,543 ordinary shares and pre-funded warrants to certain investors, expecting approximately $6.5 million in gross proceeds. The offering includes accompanying ordinary warrants exercisable at $4.20 and is expected to close on or about June 23, 2026. The company intends to use the net proceeds to support continued execution of its pivotal clinical trial for GelrinC and to advance preparation of the pre-market approval submission to the FDA.
Key figures
- Gross Proceeds
- $6.5 million
- Offering Price
- 3.5
- Shares Offered
- 1,844,543
- Ordinary Warrants
- 1,857,143
- Pre Funded Warrants
- 12600
- Warrant Exercise Price
- 4.2
- Placement Agent Fee Percent
- 7
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.